Glioma is the most common malignant primary brain tumor in adults, and its most aggressive form, glioblastoma, carries a median survival measured in months rather than years. The therapeutic arsenal remains painfully thin: surgical resection, radiation, and the chemotherapy drug temozolomide extend life only modestly, and the blood-brain barrier blocks many otherwise promising compounds from ever reaching the tumor. Against this backdrop, scientists have increasingly turned to cell death programs as therapeutic levers. Apoptosis, the quiet and orderly form of cell suicide, has long been the target of conventional cancer drugs, but tumors routinely evolve resistance to it. Pyroptosis, by contrast, is loud, inflammatory, and lytic: cells swell, rupture, and release their contents, simultaneously destroying the tumor cell and sounding an immune alarm.

The molecular machinery of pyroptosis centers on the gasdermin family of proteins. When enzymes such as caspases cleave a gasdermin protein, the released fragment migrates to the cell membrane and punches oligomeric pores into it. The cell loses its ionic balance, swells with water, and ultimately bursts, spilling damage-associated molecular patterns and inflammatory cytokines such as interleukin-1 beta into the tumor microenvironment. One family member in particular, gasdermin E, or GSDME, has attracted intense interest because it can be cleaved by caspase-3, the very executioner enzyme of apoptosis. In principle, this creates a molecular switch: a stimulus that begins as apoptotic can be diverted into pyroptosis when GSDME is present, converting a silent death into an immunostimulatory event capable of reshaping the tumor’s immune landscape.

Recognizing this potential, Hanwen Lu and Zhanxiang Wang of the First Affiliated Hospital of Xiamen University and their collaborators set out to do something that had not been done systematically before: build a dedicated library of pyroptosis-inducing compounds and filter it through the unforgiving realities of brain tumor pharmacology. The team assembled their library by combining commercially available pyroptosis inducers with candidates harvested from an exhaustive mining of the PubMed and Web of Science literature. But identifying a molecule that triggers pyroptosis in a dish is only the first hurdle. For a brain cancer drug, the compound must also survive the gauntlet of drug-likeness filters and, crucially, cross the blood-brain barrier, the tightly sealed endothelial lining that excludes the vast majority of small molecules from the central nervous system.

To solve this, the researchers applied a sequential computational and pharmacological funnel. First came Lipinski’s rule of five, the classic checklist of molecular weight, hydrogen-bond donors and acceptors, and lipophilicity that predicts oral absorbability. Next, they used predictive models of blood-brain barrier permeability, followed by central nervous system multiparameter optimization scoring, a more sophisticated metric that balances multiple physicochemical properties to estimate the likelihood that a molecule will achieve adequate brain exposure without unacceptable side effects. Stringent descriptor-based criteria narrowed the field further, and a final round of pharmacological curation and literature vetting elevated a short list of priority candidates. Rising to the top of that list was diacerein, a drug oncologists had never seriously considered but rheumatologists have prescribed for years.

Diacerein is an anthraquinone derivative that works as a slow-acting anti-osteoarthritic agent, traditionally understood to inhibit interleukin-1 beta signaling in cartilage. Its established safety profile, oral availability, and favorable predicted brain penetration made it an attractive repurposing candidate. In laboratory experiments, the team found that diacerein significantly inhibited the proliferation of glioma cells and suppressed tumor growth in animal models. But the mechanism they uncovered was far more interesting than simple growth arrest. Treatment with diacerein activated caspase-3, the canonical apoptotic executioner, and simultaneously triggered the cleavage of GSDME, the gasdermin protein that converts caspase-3 activity into pyroptotic membrane rupture. In other words, the drug appeared to push glioma cells down a hybrid death pathway that begins with apoptosis and culminates in pyroptosis-like lysis.

To confirm that GSDME was not merely a bystander in this process, the researchers performed loss-of-function experiments. When they knocked down GSDME in glioma cells, the cytotoxic punch of diacerein was substantially blunted: cell viability recovered, and the drug’s killing efficiency dropped. This partial rescue demonstrates that GSDME is functionally required for a significant share of diacerein-induced glioma cell death, anchoring the drug’s effect in the pyroptotic pathway the screen was designed to find. The team also traced changes in inflammation-related signaling, observing reduced activity along the interleukin-1 beta, NF-kappa B, and phosphorylated STAT3 axes. Because these pathways sit at the heart of macrophage-mediated inflammation, the authors suggest the drug may also alter macrophage-related immune dynamics within the tumor microenvironment in living animals, a possibility with major implications given the prominent role of tumor-associated macrophages in glioma immunosuppression.

The implications extend beyond a single molecule. The study validates a repurposing strategy that begins with a cell death mechanism rather than a molecular target, then filters candidate drugs through the pharmacological constraints of the diseased tissue. This pyroptosis-oriented pipeline could in principle be rerun for other cancers of the central nervous system, or adapted to other lytic death programs such as necroptosis and ferroptosis. It also illustrates the growing power of literature mining as a discovery tool: by systematically extracting pyroptosis-inducing activity from thousands of published pharmacological studies, the team assembled a candidate pool that no single laboratory’s compound collection would have contained. The approach effectively converts the accumulated knowledge of pharmacology into a searchable, filterable database of mechanism-directed therapeutics.

Considerable work remains before diacerein could reach glioma patients. The doses used in laboratory and animal studies may not map directly onto the exposures achievable and tolerable in humans, and the authors evaluated brain exposure using liquid chromatography-tandem mass spectrometry methods developed specifically for this study, but clinical pharmacokinetics in glioma patients, where the blood-brain barrier is often locally disrupted yet heterogeneously intact, will need dedicated investigation. The precise molecular target through which diacerein initiates caspase-3 activation in glioma cells also remains to be fully defined, and the immunological consequences of triggering pyroptosis inside the brain, an organ exquisitely sensitive to inflammation, must be carefully characterized. Nevertheless, the fact that diacerein is already an approved, well-characterized medicine with a known safety record could substantially shorten the path from bench to bedside, potentially through investigator-initiated clinical trials in recurrent glioma, where new options are desperately needed and the regulatory bar for repurposed drugs is lower than for entirely novel agents.

For a disease that has defeated nearly every therapeutic innovation thrown at it, the idea that an arthritis pill sitting in pharmacy shelves worldwide might recruit the immune system against glioma through gasdermin pores is the kind of unexpected twist that drug repurposing was made for. The Xiamen team’s work provides both a concrete candidate and a reusable discovery framework, suggesting that the next breakthrough in brain cancer may not come from a molecule designed from scratch, but from an old drug viewed through an entirely new biological lens.

Subject of Research: Pyroptosis-oriented drug repurposing identifies diacerein as a therapeutic candidate for glioma

Article Title: Pyroptosis-oriented drug discovery identifies diacerein as a promising therapeutic candidate for glioma

Article References: Lu, H., & Wang, Z. (2026). Pyroptosis-oriented drug discovery identifies diacerein as a promising therapeutic candidate for glioma. BMC Medicine. https://doi.org/10.1186/s12916-026-05187-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05187-y

Keywords: glioma, diacerein, pyroptosis, GSDME, caspase-3, drug repurposing, blood-brain barrier, immune microenvironment, macrophage, NF-kappa B, IL-1 beta, BMC Medicine